Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Important Information Related to Your Request:
The material below is provided in response to your specific search
for information on UCBCOMPASS® and may
contain information that is not part of the FDA-approved Prescribing
Information. UCB, Inc. does not recommend or endorse the use of its
products in a manner not consistent with the approved Prescribing
Information. Please review the Full Prescribing
Information.